| Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment RM Zemek, E De Jong, WL Chin, IS Schuster, VS Fear, TH Casey, ... Science translational medicine 11 (501), eaav7816, 2019 | 184 | 2019 |
| Sensitizing the tumor microenvironment to immune checkpoint therapy RM Zemek, WL Chin, AK Nowak, MJ Millward, RA Lake, WJ Lesterhuis Frontiers in immunology 11, 223, 2020 | 61 | 2020 |
| A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma WS Lam, J Creaney, FK Chen, WL Chin, S Muruganandan, ... Lung Cancer 140, 87-92, 2020 | 20 | 2020 |
| Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice RM Zemek, WL Chin, VS Fear, B Wylie, TH Casey, C Forbes, CM Tilsed, ... Nature Communications 13 (1), 4895, 2022 | 17 | 2022 |
| Characterising the binding specificities of the subunits associated with the KMT2/Set1 histone lysine methyltransferase BL Murton, WL Chin, CP Ponting, LS Itzhaki Journal of molecular biology 398 (4), 481-488, 2010 | 17 | 2010 |
| Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors SJ Dart, AM Cook, MJ Millward, AM McDonnell, WL Chin, MU Hakeem, ... Scientific Reports 11 (1), 15312, 2021 | 16 | 2021 |
| Immune checkpoint inhibitor therapy for malignant pleural mesothelioma AK Nowak, WL Chin, S Keam, A Cook Lung Cancer 162, 162-168, 2021 | 7 | 2021 |
| CD4+ T cells drive an inflammatory, TNF-α/IFN-rich tumor microenvironment responsive to chemotherapy CM Tilsed, N Principe, J Kidman, WL Chin, MLO Morales, RM Zemek, ... Cell Reports 41 (13), 2022 | 6 | 2022 |
| Comprehensive testing of chemotherapy and immune checkpoint blockade in preclinical cancer models identifies additive combinations N Principe, WJ Aston, DE Hope, CM Tilsed, SA Fisher, L Boon, IM Dick, ... Frontiers in immunology 13, 872295, 2022 | 5 | 2022 |
| Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci. Transl. Med. 11, eaav7816 RM Zemek, E De Jong, WL Chin, IS Schuster, VS Fear, TH Casey, ... | 5 | 2019 |
| Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery WL Chin, RM Zemek, WJ Lesterhuis, T Lassmann Molecular Systems Design & Engineering 4 (4), 689-700, 2019 | 4 | 2019 |
| LBA99 First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line … A Helland, VD Haakensen, AK Ojlert, SMH Thunold, AK Nowak, WL Chin, ... Annals of Oncology 34, S1337, 2023 | 1 | 2023 |
| UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma–a phase II randomised trial VD Haakensen, ÅK Öjlert, S Thunold, S Farooqi, AK Nowak, WL Chin, ... European Journal of Cancer, 113973, 2024 | | 2024 |
| Spectral detection of condition-specific biological pathways in single-cell gene expression data WL Chin, LP dos Santos, M Small, WJ Lesterhuis, T Lassmann bioRxiv, 2023.03. 12.532317, 2023 | | 2023 |
| Temporally restricted activation of IFNβ signaling determines response to immune checkpoint therapy R Zemek, WL Chin, V Fear, B Wylie, T Casey, C Forbes, C Tilsed, L Boon, ... | | 2021 |
| A bioinformatics approach to biomarker validation using publically available RNAseq data from immunotherapy trials WL Chin, R Zemek, RA Lake, AK Nowak, T Lassmann, W Lesterhuis ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 14, 145-146, 2018 | | 2018 |
